Status:

COMPLETED

Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag

Lead Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions:

Jet Lag

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

This study will examine the effects of cortisol (hydrocortisone), melatonin, a combination of cortisol and melatonin, and placebo (an inactive substance) on jet lag symptoms. Jet lag is a term used to...

Detailed Description

Jet lag resulting from rapid flight across several time zones is a common complaint of travelers. The symptoms of jet lag are primarily described as daytime sleepiness, fatigue, and impaired mental ef...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Age greater than or equal to 18, but less than or equal to 65, male or female.
  • Normal physical exam and laboratory results.
  • Negative urinary pregnancy test 1 week prior to travel (pre-menopausal women).
  • Planned eastward flight crossing 6-8 time zones between 30n and 50n latitudes.
  • A minimum stay of 7 - 10 days abroad.
  • Willingness and anticipated ability to comply with study procedures, including sleep and wake hours, saliva collection and questionnaire completion.
  • Written informed consent.
  • EXCLUSION CRITERIA:
  • BMI less than or equal to 20 or greater than or equal to 30 kg/m.
  • Current psychiatric or seizure disorder.
  • Current sleep disorder as assessed by presence of sleep apnea, daytime napping of more than 20 minutes, chronic fatigue.
  • History of Cushing's syndrome.
  • Serious chronic medical condition.
  • Current drug or alcohol abuse.
  • SGOT or SGPT greater than three-fold normal.
  • Current pregnancy or lactation.
  • Current use of CPAP.
  • Chronic use of beta-blockers (which inhibit melatonin secretion), anti-epileptic agents, anticoagulants, fluvoxamine, nifedipine or soporific or sleep-inducing agents (including benzodiazepines, melatonin), or glucocorticoids.
  • Fasting blood glucose greater than 110 mg/dL or known diabetes.

Exclusion

    Key Trial Info

    Start Date :

    December 21 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 14 2007

    Estimated Enrollment :

    57 Patients enrolled

    Trial Details

    Trial ID

    NCT00097474

    Start Date

    December 21 2004

    End Date

    November 14 2007

    Last Update

    December 26 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center

    Bethesda, Maryland, United States, 20892